直接抗病毒药物治疗后慢性丙型肝炎相关失代偿期肝硬化的再代偿:丙型肝炎病毒消除计划中的前瞻性队列研究
该前瞻性队列研究纳入1152例丙型肝炎病毒相关失代偿期肝硬化患者,评估直接抗病毒药物治疗后持续病毒学应答(SVR-12)、再代偿(Baveno VII标准)及生存情况。结果显示SVR-12为81.8%,追加治疗后最终SVR达90.8%;再代偿发生率为24.7%,中位时间16.5个月。尽管获得SVR-12,仍有19%患者出现进一步失代偿,2.9%发生肝细胞癌。
要点
- 失代偿期丙肝肝硬化患者直接抗病毒药物治疗后SVR-12为81.8%,追加治疗后最终SVR达90.8%。
- 再代偿发生率为24.7%,中位时间16.5个月(四分位距14.5-20.5个月)。
- 低胆红素、低INR、无大食管静脉曲张或无胃静脉曲张预测再代偿。
核心结论
- 在以基因3型为主的丙型肝炎病毒相关失代偿期肝硬化人群中,SVR-12在4年随访期间使24.7%的患者实现再代偿。
- 尽管获得SVR-12,仍有19%患者出现新的肝失代偿,2.9%发生肝细胞癌。
研究设计与样本
- 前瞻性队列研究,纳入2018年7月至2023年7月期间接受直接抗病毒药物治疗的慢性丙型肝炎相关失代偿期肝硬化患者。
- 共纳入1152例失代偿期肝硬化患者(年龄53.2±11.5岁;63%为男性;MELD-Na评分16.5±4.6;87%为基因3型),评估SVR-12及每6个月随访。
主要发现
- 第一疗程后SVR-12为81.8%,追加治疗后最终SVR为90.8%。
- 失代偿事件包括腹水1098例(95.3%)、肝性脑病191例(16.6%)、静脉曲张出血284例(24.7%);腹水消退率为86%,其中24%患者实现利尿剂停用。
- 再代偿发生于284例(24.7%),中位时间16.5个月(四分位距14.5-20.5个月)。
- 多变量Cox比例风险分析显示,低胆红素(aHR 0.6;95%CI 0.5-0.8;P<0.001)、INR(aHR 0.2;95%CI 0.1-0.3;P<0.001)、无大食管静脉曲张(aHR 0.4;95%CI 0.2-0.9;P=0.048)或无胃静脉曲张(aHR 0.5;95%CI 0.3-0.7;P=0.022)预测再代偿。
- 门静脉高压进展158例(13.7%),再出血率4%;既往失代偿伴静脉曲张出血(aHR 1.6;95%CI 1.2-2.8;P=0.042)和大静脉曲张(aHR 2.9;95%CI 1.3-6.5;P<0.001)与门静脉高压进展相关。
关键数值与推荐
- 再代偿采用Baveno VII标准定义。
- SVR-12定义为治疗结束后12周持续病毒学应答。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Chronic hepatitis C-related decompensated cirrhosis is associated with lower sustained virologic response (SVR)-12 rates and variable regression of disease severity after direct-acting antiviral agents. We assessed rates of SVR-12, recompensation (Baveno VII criteria), and survival in such patients. METHODS: Between July 2018 and July 2023, patients with decompensated chronic hepatitis C-related cirrhosis after direct-acting antiviral agents treatment were evaluated for SVR-12 and then had 6-monthly follow-up. RESULTS: Of 6516 patients with cirrhosis, 1152 with decompensated cirrhosis (age 53.2 ± 11.5 years; 63% men; Model for End-stage Liver Disease-Sodium [MELD-Na]: 16.5 ± 4.6; 87% genotype 3) were enrolled. SVR-12 was 81.8% after 1 course; ultimately SVR was 90.8% after additional treatment. Decompensation events included ascites (1098; 95.3%), hepatic encephalopathy (191; 16.6%), and variceal bleeding (284; 24.7%). Ascites resolved in 86% (diuretic withdrawal achieved in 24% patients). Recompensation occurred in 284 (24.7%) at a median time of 16.5 (interquartile range, 14.5-20.5) months. On multivariable Cox proportional hazards analysis, low bilirubin (adjusted hazard ratio [aHR], 0.6; 95% confidence interval [CI], 0.5-0.8; P < 0.001), international normalized ratio (aHR, 0.2; 95% CI, 0.1-0.3; P < 0.001), absence of large esophageal varices (aHR, 0.4; 95% CI, 0.2-0.9; P = 0.048), or gastric varices (aHR, 0.5; 95% CI, 0.3-0.7; P = 0.022) predicted recompensation. Portal hypertension progressed in 158 (13.7%) patients, with rebleed in 4%. Prior decompensation with variceal bleeding (aHR, 1.6; 95% CI, 1.2-2.8; P = 0.042), and presence of large varices (aHR, 2.9; 95% CI, 1.3-6.5; P < 0.001) were associated with portal hypertension progression. Further decompensation was seen in 221 (19%); 145 patients died and 6 underwent liver transplantation. A decrease in MELDNa of ≥3 was seen in 409 (35.5%) and a final MELDNa score of <10 was seen in 335 (29%), but 2.9% developed hepatocellular carcinoma despite SVR-12. CONCLUSIONS: SVR-12 in hepatitis C virus-related decompensated cirrhosis in a predominant genotype 3 population led to recompensation in 24.7% of patients over a follow-up of 4 years in a public health setting. Despite SVR-12, new hepatic decompensation evolved in 19% and hepatocellular carcinoma developed in 2.9% of patients. (ClinicalTrials.gov, Number: NCT03488485).
引用
- Premkumar M, Dhiman RK, Duseja A, et al. Recompensation of Chronic Hepatitis C-Related Decompensated Cirrhosis Following Direct-Acting Antiviral Therapy: Prospective Cohort Study From a Hepatitis C Virus Elimination Program. Gastroenterology. 2024. PMID: 39181168. doi:10.1053/j.gastro.2024.08.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。